admin_auro

March 3, 2018

Published by admin_auro at March 3, 2018

Categories

Molecular therapy for tuberculosis: Carvedilol (brand name: Coreg), used in treatment of congestive heart failure and left ventricular dysfunction, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via up regulation of its target gene, 3/March/2018, 9.23 am

Introduction: What they say: A study from the Singapore Immunology Network, Agency for Science, Technology and Research, Singapore; and Lee Kong Chian School of Medicine, Nanyang […]

March 3, 2018

Published by admin_auro at March 3, 2018

Categories

Molecular therapy for body weight control, energy homeostasis and TIIDM: Lactulose (Brand names: Cholac, Generlac, Consulose, Duphalac), a non-absorbable sugar that aids in the treatment of constipation and hepatic encephalopathy, decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 3/March/2017, 9.10 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]

March 3, 2018

Published by admin_auro at March 3, 2018

Categories

Polyamine-based therapy for diabetes (TIDM): Spermidine, a natural polyamine, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 3/March/2018, 8.47 am

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, […]

March 3, 2018

Published by admin_auro at March 3, 2018

Categories

Ideas
NAFLD

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Sirolimus, an immunosuppressant and longevity promoter, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 3/March/2018, 8.38 am

Significance of the study: Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to […]